At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-blind, Double-dummy, Placebo-controlled, Dose-ranging Phase II Study Assessing Ranolazine in the Maintenance of Sinus Rhythm After Electrical Cardioversion in Patients With Non-permanent Atrial Fibrillation.
In Brief
A Phase 2 clinical trial evaluating Ranolazine and Placebo for Persistent Atrial Fibrillation. Completed, enrolled 241 participants across 4 sites in 4 countries.
Detailed Summary
Dose-ranging Phase II study testing the efficacy and safety of 3 doses of Ranolazine (low, intermediate and high, given BID) versus placebo in maintaining sinus rhythm after successful electrical cardioversion in patients with persistent atrial fibrillation (AFib). After successful cardioversion and subsequent randomisation, patients report trans-telephonic EGCs on a daily basis to a central core ECG facility. Maximum treatment duration is 112 days (16 weeks).
Study Details
Timeline
Interventions
Oral administration, BID; for a maximum of 112 days.
Oral administration, BID; for a maximum of 112 days.
Oral administration, BID; for a maximum of 112 days.
Oral administration, BID; for a maximum of 112 days.